Verona Pharma PLC
VRNA106.910USD
0.000
Close 12/12, 16:00（ET）Quotes delayed by 15 min
73.55BMarket Cap
LossP/E TTM
More Details of Verona Pharma PLC Company
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLC Info
Ticker SymbolVRNA
Company nameVerona Pharma PLC
IPO dateMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Number of employees209
Security typeDepository Receipt
Fiscal year-endMar 30
AddressRiverside
CityLONDON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited Kingdom
Postal codeSE1 2RE
Phone442032834200
Websitehttps://www.veronapharma.com/
Ticker SymbolVRNA
IPO dateMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Company Executives of Verona Pharma PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
Other
77.14%
Shareholders
Shareholders
Proportion
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
Other
77.14%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.35%
Investment Advisor/Hedge Fund
19.15%
Investment Advisor
14.06%
Research Firm
7.21%
Individual Investor
5.62%
Venture Capital
4.92%
Private Equity
4.03%
Family Office
1.17%
Bank and Trust
0.41%
Other
4.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
467
76.61M
88.88%
-7.12M
2025Q2
423
82.86M
96.18%
-3.71M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
3.38M
3.93%
-73.90K
-2.14%
Jun 30, 2025
Ali (Behbahani)
3.19M
3.7%
+3.19M
--
Jan 16, 2025
New Enterprise Associates (NEA)
2.26M
2.63%
-425.43K
-15.82%
Jun 30, 2025
Goldman Sachs & Company, Inc.
2.61M
3.03%
+1.58M
+152.32%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Disciplined Volatility Equity Active ETF
0%
AltShares Merger Arbitrage ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Rayliant Quantitative Developed Market Equity ETF
0%
Calvert International Responsible Index ETF
0%
iShares Biotechnology ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
JPMorgan Healthcare Leaders ETF
0%
Global X Guru Index ETF
0%
View more
iShares Disciplined Volatility Equity Active ETF
Proportion0%
AltShares Merger Arbitrage ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Rayliant Quantitative Developed Market Equity ETF
Proportion0%
Calvert International Responsible Index ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0%
JPMorgan Healthcare Leaders ETF
Proportion0%
Global X Guru Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Verona Pharma PLC?
The top five shareholders of Verona Pharma PLC are:
Frazier Life Sciences Management, L.P. holds 3.38M shares, accounting for 3.93% of the total shares.
Ali (Behbahani) holds 3.19M shares, accounting for 3.70% of the total shares.
New Enterprise Associates (NEA) holds 2.26M shares, accounting for 2.63% of the total shares.
Goldman Sachs & Company, Inc. holds 2.61M shares, accounting for 3.03% of the total shares.
Frazier Life Sciences Management, L.P. holds 3.38M shares, accounting for 3.93% of the total shares.
Ali (Behbahani) holds 3.19M shares, accounting for 3.70% of the total shares.
New Enterprise Associates (NEA) holds 2.26M shares, accounting for 2.63% of the total shares.
Goldman Sachs & Company, Inc. holds 2.61M shares, accounting for 3.03% of the total shares.
What are the top three shareholder types of Verona Pharma PLC?
The top three shareholder types of Verona Pharma PLC are:
Pentwater Capital Management LP
HBK Investments, L.P.
Fidelity Investments Canada ULC
Pentwater Capital Management LP
HBK Investments, L.P.
Fidelity Investments Canada ULC
How many institutions hold shares of Verona Pharma PLC (VRNA)?
As of 2025Q3, 467 institutions hold shares of Verona Pharma PLC, with a combined market value of approximately 76.61M, accounting for 88.88% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.30%.
What is the biggest source of revenue for Verona Pharma PLC?
In --, the -- business generated the highest revenue for Verona Pharma PLC, amounting to -- and accounting for --% of total revenue.
